Management of Hepatitis C Infection

  • Authors: Jordan J. Feld, MD, MPH; Hemant Shah, MD, MScCH HPTE (More Info)
  • Editor In Chief: Stefan Zeuzem, MD
  • Last Reviewed: 7/24/18 (What's New)

Summary

  • Subgenotype 1a has lower barrier to resistance to protease and NS5A inhibitors than subgenotype 1b[Halfon 2011]
  • Presence of NS5A RAVs at baseline in patients with genotype 1a HCV infection lowers SVR rate for elbasvir/grazoprevir, necessitating longer duration therapy and/or addition of ribavirin
  • Response to some interferon-free DAA therapies varies by genotype

Action required